F.I. Proctor Foundation, University of California, San Francisco, California 94143-0412, USA.
Ocul Immunol Inflamm. 2009 Nov-Dec;17(6):431-3. doi: 10.3109/09273940903267936.
To describe the use of fluocinolone acetonide implants (Retisert) in Vogt-Koyanagi-Harada disease (VKH).
Interventional case series.
Retrospective review of medical records.
Two patients with VKH requiring high-dose systemic corticosteroid therapy to control their inflammation and bilateral serous retinal detachments received bilateral fluocinolone acetonide implants. Upon tapering of systemic corticosteroids, one patient had recurrent serous retinal detachments and the other patient's anterior chamber and vitreous inflammation returned.
The authors' experience with fluocinolone acetonide implants in VKH has been mixed with an inability to fully taper off of systemic corticosteroids.
描述在 Vogt-小柳-原田病（VKH）中使用氟轻松醋酸酯植入物（Retisert）的情况。
介入性病例系列研究。
回顾性病历审查。
两名 VKH 患者需要大剂量全身皮质类固醇治疗来控制炎症和双侧浆液性视网膜脱离，他们接受了双侧氟轻松醋酸酯植入物治疗。在逐渐减少全身皮质类固醇治疗剂量后，一名患者出现复发性浆液性视网膜脱离，另一名患者的前房和玻璃体炎症复发。
作者在 VKH 中使用氟轻松醋酸酯植入物的经验喜忧参半，无法完全停用全身皮质类固醇。
